Medically Attended Acute Adverse Events in Pregnant People After Coronavirus Disease 2019 (COVID-19) Booster Vaccination
- PMID: 37167612
- PMCID: PMC10278564
- DOI: 10.1097/AOG.0000000000005241
Medically Attended Acute Adverse Events in Pregnant People After Coronavirus Disease 2019 (COVID-19) Booster Vaccination
Abstract
In this multisite, observational, matched cohort study of more than 80,000 pregnant people, receipt of an mRNA monovalent coronavirus disease 2019 (COVID-19) booster vaccination in pregnancy was not associated with increased risk for thrombocytopenia, myocarditis, venous thromboembolism, ischemic stroke, or other serious adverse events within 21 or 42 days after booster vaccination. The mRNA monovalent COVID-19 booster in pregnancy was associated with an increased risk for medically attended malaise or fatigue within 7 days of vaccination (adjusted rate ratio [aRR] 3.64, 95% CI 2.42-5.48) and lymphadenopathy or lymphadenitis within 21 days (aRR 3.25, 95% CI 1.67-6.30) or 42 days (aRR 2.18, 95% CI 1.33-3.58) of vaccination. Our findings are consistent with prior evaluations of the primary COVID-19 vaccine series and are reassuring with respect to COVID-19 booster vaccination in pregnancy.
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
Financial Disclosure Gabriela Vazquez-Benitez reports money was paid to her institution from AbbVie and Sanofi Pasteur, both for research not related to this work. Candace C. Fuller's institution has received research funding from Pfizer and Johnson & Johnson for unrelated studies. Darios Getahun reports money was paid to their institution from Hologic Inc. and Johnson & Johnson. Simon J. Hambidge reports receiving payment through his employment from Denver Health. He sits on the board for the Colorado Community Health Network and the Denver Health Medical Plan (all unpaid). Heather S. Lipkind received payment from the Data Safety and Monitoring Board for Pfizer for the COVID-19 vaccination. Allison L. Naleway reports money was paid to her institution from Pfizer and Vir Biotechnology. Jennifer Nelson reports receiving payment from Harvard Pilgrim Health Care for statistical consulting and from Elsevier Publishing for service as an Associate Editor for the journal Vaccine. Kimberly K. Vesco's institution received Pfizer Independent Grants for Learning and Change. The other authors did not report any potential conflicts of interest.
Figures
![Fig. 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10278564/bin/ong-142-125-g002.gif)
![Figure](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10278564/bin/ong-142-125-g003.gif)
Similar articles
-
Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.MMWR Morb Mortal Wkly Rep. 2023 Jan 13;72(2):39-43. doi: 10.15585/mmwr.mm7202a5. MMWR Morb Mortal Wkly Rep. 2023. PMID: 36634021 Free PMC article.
-
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.BMJ. 2022 Jul 13;378:e070483. doi: 10.1136/bmj-2022-070483. BMJ. 2022. PMID: 35831006 Free PMC article.
-
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.BMJ. 2022 Jul 13;378:e069445. doi: 10.1136/bmj-2021-069445. BMJ. 2022. PMID: 35830976 Free PMC article. Review.
-
Adverse events following third dose of mRNA COVID-19 vaccination among nursing home residents who received the primary series.J Am Geriatr Soc. 2022 Jun;70(6):1642-1647. doi: 10.1111/jgs.17812. Epub 2022 Apr 27. J Am Geriatr Soc. 2022. PMID: 35460263 Free PMC article.
-
COVID-19 vaccination among pregnant people in the United States: a systematic review.Am J Obstet Gynecol MFM. 2022 Jul;4(4):100616. doi: 10.1016/j.ajogmf.2022.100616. Epub 2022 Mar 10. Am J Obstet Gynecol MFM. 2022. PMID: 35283351 Free PMC article. Review.
Cited by
-
Prenatal Maternal Immunization for Infant Protection: A Review of the Vaccines Recommended, Infant Immunity and Future Research Directions.Pathogens. 2024 Feb 23;13(3):200. doi: 10.3390/pathogens13030200. Pathogens. 2024. PMID: 38535543 Free PMC article. Review.
-
Description of maternal and neonatal adverse events in pregnant people immunised with COVID-19 vaccines during pregnancy in the CLAP NETWORK of sentinel sites. Nested case-control analysis of the immunization-associated risk: A study protocol.BMJ Open. 2024 Jan 29;14(1):e073095. doi: 10.1136/bmjopen-2023-073095. BMJ Open. 2024. PMID: 38286697 Free PMC article.
References
-
- Villar J, Soto Conti CP, Gunier RB, Ariff S, Craik R, Cavoretto PI, et al. . Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. Lancet 2023;401:447–57. doi: 10.1016/S0140-6736(22)02467-9 - DOI - PMC - PubMed
-
- Schrag SJ, Verani JR, Dixon BE, Page JM, Butterfield KA, Gaglani M, et al. . Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of Delta and Omicron variant predominance in the United States. JAMA Netw Open 2022;5:e2233273. doi: 10.1001/jamanetworkopen.2022.33273 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical